Zoloft Tapering Guide
sertraline
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Sertraline is an SSRI antidepressant approved for major depressive disorder, OCD, panic disorder, PTSD, social anxiety disorder, and premenstrual dysphoric disorder. It is one of the most widely prescribed antidepressants worldwide.
25mg, 50mg, 100mg, 200mg
Tablets: 25mg, 50mg, 100mg; Oral concentrate: 20mg/mL
Category C (risk cannot be ruled out)
Mechanism of Action
Potent and selective inhibitor of serotonin reuptake at the presynaptic membrane (SERT), with minimal effects on norepinephrine and dopamine reuptake. Also has mild affinity for the dopamine transporter.
Taper Notes
Liquid formulation available for precise dosing. Hyperbolic taper recommended.
Hyperbolic Tapering Guidance
Follow hyperbolic reduction schedule. Liquid concentrate (20mg/mL) useful for fine adjustments.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | ~4 weeks | Larger steps using available tablet strengths. Generally well tolerated at higher doses. |
| Middle reductions | 4-6 weeks | Smaller tablet strengths for more gradual changes. Monitor for GI disturbance. |
| Lower dose reductions | 6-8 weeks | Ask your prescriber about oral concentrate for more precise adjustments at lower doses. |
| Final reductions | 6-10 weeks | The lowest doses often require the slowest approach. Work with your prescriber on liquid dosing. |
Withdrawal Timeline
1-2 days after dose reduction
3-7 days
2-3 weeks for acute symptoms
GI symptoms and irritability may linger 4-8 weeks. Brain zaps typically resolve within 1 month.
Community Tips
Practical insights shared by members tapering Zoloft. Not medical advice — always consult your prescriber.
- 1Ask your prescriber about Zoloft oral concentrate — it allows more precise adjustments than tablet splitting.
- 2GI upset is often the first withdrawal symptom to appear. Ginger tea and smaller, more frequent meals can help.
- 3The final stretch of tapering is disproportionately difficult for many members. Patience is key.
- 4Sertraline has mild dopaminergic activity — some members report motivational dips during the taper that improve after stabilization.
- 5Track your symptoms daily in your taper journal. Zoloft withdrawal can be subtle and creep up gradually.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (serotonin syndrome risk)
- Pimozide — contraindicated
- Disulfiram — oral concentrate contains alcohol
Food Interactions
- Food increases peak plasma levels by ~25%
- Oral concentrate must be diluted before use; avoid mixing with grapefruit juice
- Avoid alcohol during treatment
Contraindications
- MAOIs within 14 days
- Pimozide
- Disulfiram (oral concentrate contains alcohol)
Toxicity
Serotonin syndrome in overdose or with serotonergic combinations. QT prolongation reported rarely. GI bleeding risk increased with NSAIDs.
Pharmacokinetics
ADME Profile
Slowly absorbed after oral administration, Tmax 4.5–8.4 hours. Bioavailability subject to extensive first-pass metabolism. Food increases Tmax slightly.
~20 L/kg
Extensive hepatic metabolism primarily via CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 to N-desmethylsertraline (substantially less active).
Renal (~40–45% as metabolites) and fecal (~40–45%). Less than 0.2% excreted unchanged in urine.
~98%
~1.5 L/min (oral clearance)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Zoloft (sertraline) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.